The hidden biology of addiction and cancer

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma brain metastases

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resectable melanoma

Cemiplimab reduces disease recurrence as adjuvant therapy for cutaneous squamous cell carcinoma

Nivolumab/ipilimumab followed by BRAF/MEK inhibitors preferred sequence for BRAF-positive advanced melanoma

EGFR shows to be a promising therapeutic target in NF1 mutant melanoma

Understanding the role of the Tanzania Medicines and Medical Devices Authority

Understanding Uganda's drug safety regulations

Expectations and priorities of older patients with cancer: the PRIORITY multicenter cohort study

Neoadjuvant ipilimumab added to nivolumab improves outcomes in resectable advanced melanoma

Assessment of suicide risk in cancer patients

Association of adult attachment with delays in accessing specialist care in women with ovarian cancer